The new non-HIV antivirals and antifungals: Review and assessment for the formulary
Tags: ANTIVIRAL agents; ANTIFUNGAL agents
Related Articles
- New antiviral and antifungal drugs. Davey, Peter G. // BMJ: British Medical Journal (International Edition);3/24/90, Vol. 300 Issue 6727, p793
Features antiviral and antifungal drugs. Presentation of indications, dosage and costs of the drugs; Efficacy of Acyclovir as eye ointment; Administration of interferons in patients with hairy cell leukemia.
- Prescribing update. Saunders, Carol S. // Patient Care;1/30/2001, Vol. 35 Issue 2, p13
Presents updates on drug prescription in the United States as of January 30, 2001. Approval for an anti-HIV drug prescription; Approval for an antihistamine nasal spray; Approval for the formulation of antifungal drugs.
- TREE BARK YIELDS ANTIFUNGAL. // AIDS Patient Care & STDs;May2000, Vol. 14 Issue 5, p286
Reports that bark from trees found in Africa and Argentina may yield two treatment from AIDS treatments, including an antifungal and an antiviral compound. Effect of the antifungal compound on mouth infections; Development of the anti-AIDS compound in Spain.
- Drugs in dermatological practice: Relationship to food. Prabhu, Smitha; Shenoi, Shrutakirthi D. // Indian Journal of Dermatology, Venereology & Leprology;Jul/Aug2003, Vol. 69 Issue 4, p305
Presents a compilation of drugs in dermatological practice in relationship to food. Antibiotics before food; Antifungals with food; Antivirals after food.
- Interferon-? as an Antifungal. Stevens, David A.; Brummer, Elmer; Clemons, Karl V. // Journal of Infectious Diseases;9/16/2006, Vol. 194, pS33
The article relates one of the contributions of scientist Thomas Merigan related to interferon-? as an antifungal agent. It emphasizes Merigan's role of helping to bring interferon to the front of consciousness and cognizance to the populace. To give more light on the matter, details of the...
- Infectious disease market: patent expiries force leading players to adapt. // PharmaWatch: Monthly Review;Mar2008, Vol. 7 Issue 3, p30
The article focuses on the decline of antibiotics and antifungals in 2005-2006 because of a glut of patent expiries of major products. It notes that the $38 billion antibiotics for anti-infectives can be subdivided into the antibiotic, antifungal, antiviral and HIV sectors. The antivirals sector...
- Differential response to interferon-? therapy in a family with dominant negative partial interferon-? receptor1 deficiency. Smyth, Anita E.; Jackson, Paul; Lammas, David; Asghar, M. Suhail; Crockard, Alistair D.; Casanova, Jean-Laurent; Kumararatne, Dinakantha S.; Edgar, J. David M. // European Journal of Pediatrics;Jan2006, Vol. 165 Issue 1, p71
This article presents a study on the use of interferon-? therapy in the treatment of negative partial interferon-? receptor1 (IFN-?R1) deficiency. A diagnosis of dominant negative IFN-?R1 was conducted with antimycobacterial treatment for several months. There was no immediate response to the...
- Antimicrobial Peptides: Multifunctional Drugs for Different Applications. Brandenburg, Lars-Ove; Merres, Julika; Albrecht, Lea-Jessica; Varoga, Deike; Pufe, Thomas // Polymers (20734360);Mar2012, Vol. 4 Issue 1, p539
Antimicrobial peptides (APs) are an important part of the innate immune system in epithelial and non-epithelial surfaces. So far, many different antimicrobial peptides from various families have been discovered in non-vertebrates and vertebrates. They are characterized by antibiotic, antifungal...
- Continuing Education: Clinical update on opportunistic infections in transplantation. // American Journal of Health-System Pharmacy;4/15/2005 Supplement 1, Vol. 62, pS22
Presents the learning objectives and self-assessment questions for pharmacists on the opportunistic infections in transplantation. Causes, risk factors, patient presentation and trends of cytomegalovirus infections in transplant recipients; Efficacy of prophylactic antiviral drug therapy;...
